Technical Analysis for GNTA - Genenta Science S.p.A.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bullish Setup | Bullish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| 20 DMA Resistance | Bearish | 6.86% | |
| New Downtrend | Bearish | 6.86% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 6.86% | |
| Wide Bands | Range Expansion | 6.86% | |
| Down 3 Days in a Row | Weakness | 6.86% | |
| 20 DMA Resistance | Bearish | 2.16% | |
| Wide Bands | Range Expansion | 2.16% |
| Alert | Time |
|---|---|
| Non-ADX 1,2,3,4 Pullback Entry | about 22 hours ago |
| Rose Above Previous Day's High | about 22 hours ago |
| Rose Above 10 DMA | about 22 hours ago |
| Up 5% | about 22 hours ago |
| Up 3% | about 22 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Genenta is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). TemferonTM, which is under investigation in a Phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Solid Tumors Oncology Cancer Immunotherapy Gene Therapy Cell Biology Glioblastoma Platform Technology Brain Tumor Solid Tumor Cancers Glioblastoma Multiforme
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Solid Tumors Oncology Cancer Immunotherapy Gene Therapy Cell Biology Glioblastoma Platform Technology Brain Tumor Solid Tumor Cancers Glioblastoma Multiforme
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.28 |
| 52 Week Low | 2.2 |
| Average Volume | 15,445 |
| 200-Day Moving Average | 3.95 |
| 50-Day Moving Average | 4.60 |
| 20-Day Moving Average | 5.48 |
| 10-Day Moving Average | 5.28 |
| Average True Range | 0.53 |
| RSI (14) | 55.75 |
| ADX | 27.0 |
| +DI | 19.00 |
| -DI | 19.05 |
| Chandelier Exit (Long, 3 ATRs) | 5.68 |
| Chandelier Exit (Short, 3 ATRs) | 5.99 |
| Upper Bollinger Bands | 6.36 |
| Lower Bollinger Band | 4.60 |
| Percent B (%b) | 0.48 |
| BandWidth | 32.17 |
| MACD Line | 0.19 |
| MACD Signal Line | 0.26 |
| MACD Histogram | -0.0717 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.80 | ||||
| Resistance 3 (R3) | 5.76 | 5.60 | 5.74 | ||
| Resistance 2 (R2) | 5.60 | 5.52 | 5.62 | 5.72 | |
| Resistance 1 (R1) | 5.53 | 5.46 | 5.57 | 5.57 | 5.70 |
| Pivot Point | 5.37 | 5.37 | 5.39 | 5.39 | 5.37 |
| Support 1 (S1) | 5.30 | 5.29 | 5.34 | 5.34 | 5.20 |
| Support 2 (S2) | 5.14 | 5.23 | 5.16 | 5.18 | |
| Support 3 (S3) | 5.07 | 5.14 | 5.16 | ||
| Support 4 (S4) | 5.11 |
